These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28351555)

  • 21. Clinical management of cutaneous toxicity of anti-EGFR agents.
    Monti M; Motta S
    Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
    Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
    Reck M; Gutzmer R
    Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
    Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
    Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?
    Chan A; Tan EH
    Support Care Cancer; 2011 Oct; 19(10):1667-74. PubMed ID: 20820812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k.
    Thatcher N; Nicolson M; Groves RW; Steele J; Eaby B; Dunlop J; McPhelim J; Nijjar R; Ukachukwu I;
    Oncologist; 2009 Aug; 14(8):840-7. PubMed ID: 19679688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skin problems and EGFR-tyrosine kinase inhibitor.
    Kozuki T
    Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
    Agirgol S; Çaytemel C; Pilanci KN
    Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Manage skin toxicities associated with EGFR inhibitors.
    Becze E
    ONS Connect; 2008 Jun; 23(6):22-3. PubMed ID: 18572873
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
    J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
    Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR-targeted therapy and related skin toxicity.
    Morse L; Calarese P
    Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers.
    Kafatos G; Dube S; Burdon P; Demonty G; Flinois A; Leclerc M; Lowe K; Feudjo-Tepie M; Segaert S
    Clin Colorectal Cancer; 2020 Jun; 19(2):100-108.e9. PubMed ID: 32113902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
    Gangemi S; Franchina T; Minciullo PL; Profita M; Zanghì M; David A; Kennez I; Adamo V
    J Cell Biochem; 2013 Dec; 114(12):2673-6. PubMed ID: 23794184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors.
    Alexandrescu DT; Vaillant JG; Dasanu CA
    Clin Exp Dermatol; 2007 Jan; 32(1):71-4. PubMed ID: 17034418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.
    Braden RL; Anadkat MJ
    Support Care Cancer; 2016 Sep; 24(9):3943-50. PubMed ID: 27117557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME; Melosky BL
    Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.